Figures computed from official regulatory filings — .
Analysttarget 3.2 USD (+467%) · consensus 4.67/5 · 6 buy · 0 hold · 0 sell
Ownershipinsiders 0.48% · institutions 48.83% · short 12.4% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Tenaya Therapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
20 buys76 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Tingley Whittemore | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ali Faraz | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Tingley Whittemore | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Tingley Whittemore | Sell | $1.6K | SEC |
| Tingley Whittemore | Sell | $1.2K | SEC |
| Ali Faraz | Sell | $5.3K | SEC |
| Ali Faraz | Sell | $2.8K | SEC |
| Tingley Whittemore | Sell | $1.2K | SEC |
| Tingley Whittemore | Sell | $1.3K | SEC |
| Ali Faraz | Sell | $4.1K | SEC |
| Ali Faraz | Sell | $3.6K | SEC |
| Hyllengren Eric J | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lee June | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Walsh Jeffrey T. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Williams R Sanders | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Stehman-Breen Catherine | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Burroughs Amy L. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Parschauer Karah Herdman | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Srivastava Deepak | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Tingley Whittemore | Sell | $2.5K | SEC |
| Higa Tomohiro | Sell | $1.2K | SEC |
| Ali Faraz | Sell | $2.7K | SEC |
| TCG Opportunity III GP, LLCtrack record | Sell | $216.5K | SEC |
| TCG Opportunity III GP, LLCtrack record | Sell | $1M | SEC |